Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bioxcel Therapeutics Inc (NQ: BTAI )

18.60 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 18.60
Bid (Size) 18.16 (20)
Ask (Size) 44.00 (3)
Prev. Close 18.60
Today's Range 18.60 - 18.60
52wk Range 8.795 - 34.12
Shares Outstanding 29,009,536
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Meta Platforms To Rally Over 26%? Here Are 10 Other Analyst Forecasts For Tuesday
Morgan Stanley boosted the price target for HubSpot, Inc. (NYSE: HUBS) from $447 to $466. Morgan Stanley analyst Keith Weiss maintained an Overweight rating. HubSpot shares fell 1.9% to close at... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2023
 
Via Benzinga

Performance

YTD
-13.33%
-13.33%
1 Month
-41.73%
-41.73%
3 Month
-12.59%
-12.59%
6 Month
+64.02%
+64.02%
1 Year
-14.25%
-14.25%

More News

Read More
6 Analysts Have This to Say About BioXcel Therapeutics
Via Benzinga
Earnings Preview: BioXcel Therapeutics
Via Benzinga
Expert Ratings for BioXcel Therapeutics
Via Benzinga
Why BioXCel Therapeutics Stock Jumped This Week
Via The Motley Fool
Analyst Ratings for BioXcel Therapeutics
Via Benzinga
Is This Soaring Growth Stock a Buy?
Via The Motley Fool
BioXcel Therapeutics Unveils Complete Data From BXCL701/Keytruda Combo Study In Prostate Cancer Subtype
Via Benzinga
Analyst Reiterates This Alzheimer's Candidate As Top Idea For 2023
Via Benzinga
ChatGPT Is Just The 'Tip Of The Iceberg' In Content-Creating Artificial Intelligence; Get Ready For 'A Lot Of Disruption' (Not Just At Google)
Via Investor's Business Daily
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
Via Investor's Business Daily
Recap: BioXcel Therapeutics Q2 Earnings
Via Benzinga
BioXcel Therapeutics: Q1 Earnings Insights
Via Benzinga
2 Beaten-Down Stocks to Watch Closely Next Year
Via The Motley Fool
Why BioXcel Therapeutics Stock Triumphed This Week
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
Via Benzinga
Cramer On This Stock Down 65% Year-To-Date: 'I Do Believe It's Bottoming, But I Don't Know What Gets It Higher'
Via Benzinga
Twitter Shares Surge Around 8%, Here's 66 Biggest Movers From Yesterday
Via Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
Via Benzinga
24 Stocks Moving in Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Preview: BioXcel Therapeutics's Earnings
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.